BAFNAPHARM - Statement Of Investor Complaints For The Quarter Ended March 2022

BAFNAPHARM - Compliance Certificate For The Half Year Ended 31St March 2022

BAFNAPHARM - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

BAFNAPHARM - Closure of Trading Window

BAFNAPHARM - Appointment of Company Secretary and Compliance Officer

BAFNAPHARM - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

BAFNAPHARM - Board Meeting Outcome for Outcome Of Board Meeting Held On 21St March 2022

BAFNAPHARM - Board Meeting Intimation for To Consider Resignation And Appointment Of Company Secretary (KMP) Of The Company And Any #Part1

BAFNAPHARM - Proposed Sale Of Equity Shares Of Bafna Pharmaceuticals Limited By SRJR Life Sciences LLP, Through Open Market Sale For #Part1

Bafna Pharmaceuticals Q3FY22 net profit at Rs. 1.70 crore #BafnaPharmaceuticals #Q3FY22 #9MFY22 #ResultUpdate

BAFNAPHARM - Result

BAFNAPHARM - Board Meeting Outcome for Outcome Of Board Meeting

BAFNAPHARM - Board Meeting Intimation for Q3 Results And Other Business

BAFNAPHARM - Shareholding for the Period Ended December 31, 2021

BAFNAPHARM - Closure of Trading Window

BAFNAPHARM - Statement Of Investor Complaints For The Quarter Ended December 2021

BAFNAPHARM - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.